CoChat
Sign Up
Cited by 482Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase SignalingGenetic factors in colorectal cancer

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Open access
Zhu, Gongmin, Pei, Lijiao, Xia, Hongwei, Tang, Qiulin, Bi, Feng·2021·Molecular Cancer
DOI 10.1186/s12943-021-01441-4PMC PMC8571891
Open this paper in CoChat — free accountOpen PDF

Abstract

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma ( KRAS ) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as a molecular switch to persistently stimulate downstream signaling pathways, including cell proliferation and survival, thereby leading to tumorigenesis. Patients whose CRC harbors KRAS mutations have a dismal prognosis. Currently, KRAS mutation testing is a routine clinical practice before treating metastatic cases, and the approaches developed to detect KRAS mutations have exhibited favorable sensitivity and accuracy. Due to the presence of KRAS mutations, this group of CRC patients requires more precise therapies. However, KRAS was historically thought to be an undruggable target until the development of KRAS G12C allele-specific inhibitors. These promising inhibitors may provide novel strategies to treat KRAS -mutant CRC. Here, we provide an overview of the role of KRAS in the prognosis, diagnosis and treatment of CRC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-021-01441-4

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 100

  1. [2]Kennedy RD Bylesjo M Kerr P Davison T Black JM Kay EW Holt RJ Proutski V Ahdesmaki M Farztdinov V Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue J Clin Oncol 2011 29 4620 4626 22067406
  2. [3]Fearon ER Vogelstein B A genetic model for colorectal tumorigenesis Cell 1990 61 759 767 2188735
  3. [4]Sagaert X Vanstapel A Verbeek S Tumor heterogeneity in colorectal Cancer: what Do we know so far? Pathobiology 2018 85 72 84 29414818
  4. [5]Sasaki N Clevers H Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology Curr Opin Genet Dev 2018 52 117 122 30261425
  5. [6]Martini G Dienstmann R Ros J Baraibar I Cuadra-Urteaga JL Salva F Ciardiello D Mulet N Argiles G Tabernero J Elez E Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer Ther Adv Med Oncol 2020 12 1758835920936089 32782486 PMC7383645
  6. [8]Roth AD Tejpar S Delorenzi M Yan P Fiocca R Klingbiel D Dietrich D Biesmans B Bodoky G Barone C Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 2010 28 466 474 20008640
  7. [9]Dienstmann R Mason MJ Sinicrope FA Phipps AI Tejpar S Nesbakken A Danielsen SA Sveen A Buchanan DD Clendenning M Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study Ann Oncol 2017 28 1023 1031 28453697 PMC5406760
  8. [10]Karapetis CS Khambata-Ford S Jonker DJ O'Callaghan CJ Tu D Tebbutt NC Simes RJ Chalchal H Shapiro JD Robitaille S K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 2008 359 1757 1765 18946061
  9. [12]Hong DS Fakih MG Strickler JH Desai J Durm GA Shapiro GI Falchook GS Price TJ Sacher A Denlinger CS KRAS(G12C) inhibition with Sotorasib in advanced solid tumors N Engl J Med 2020 383 1207 1217 32955176 PMC7571518
  10. [13]Chen Z Otto JC Bergo MO Young SG Casey PJ The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules J Biol Chem 2000 275 41251 41257 11007785
  11. [15]Tsai FD Lopes MS Zhou M Court H Ponce O Fiordalisi JJ Gierut JJ Cox AD Haigis KM Philips MR K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif Proc Natl Acad Sci U S A 2015 112 779 784 25561545 PMC4311840
  12. [16]Chen W-C, To MD, Westcott PMK, Delrosario R, Kim I-J, Philips M, Tran Q, Bayani N, Balmain A. Regulation of KRAS4A/B splicing in cancer stem cells by the RBM39 splicing complex. Preprint at bioRxiv. 2019. 10.1101/646125. · DOI
  13. [18]Hancock JF Parton RG Ras plasma membrane signalling platforms Biochem J 2005 389 1 11 15954863 PMC1184533
  14. [19]Vögler O Barceló JM Ribas C Escribá PV Membrane interactions of G proteins and other related proteins Biochim Biophys Acta 2008 1778 1640 1652 18402765
  15. [21]Cherfils J Zeghouf M Regulation of small GTPases by GEFs, GAPs, and GDIs Physiol Rev 2013 93 269 309 23303910
  16. [22]Li Z Chen Y Wang D Wang G He L Suo J Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients J Int Med Res 2012 40 1589 1598 22971512
  17. [23]Cercek A Braghiroli MI Chou JF Hechtman JF Kemeny N Saltz L Capanu M Yaeger R Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations Clin Cancer Res 2017 23 4753 4760 28446505 PMC5788017
  18. [26]Smith MJ Neel BG Ikura M NMR-based functional profiling of RASopathies and oncogenic RAS mutations Proc Natl Acad Sci U S A 2013 110 4574 4579 23487764 PMC3607025
  19. [27]Imamura Y Morikawa T Liao X Lochhead P Kuchiba A Yamauchi M Qian ZR Nishihara R Meyerhardt JA Haigis KM Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers Clin Cancer Res 2012 18 4753 4763 22753589 PMC3624899
  20. [30]Camaj P Primo S Wang Y Heinemann V Zhao Y Laubender RP Stintzing S Giessen-Jung C Jung A Gamba S KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer Future Oncol 2015 11 1919 1929 26161928
  21. [31]Zocche DM Ramirez C Fontao FM Costa LD Redal MA Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer Front Genet 2015 6 116 25870609 PMC4378307
  22. [33]Loupakis F Ruzzo A Cremolini C Vincenzi B Salvatore L Santini D Masi G Stasi I Canestrari E Rulli E KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 2009 101 715 721 19603018 PMC2736831
  23. [34]Douillard JY Oliner KS Siena S Tabernero J Burkes R Barugel M Humblet Y Bodoky G Cunningham D Jassem J Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 2013 369 1023 1034 24024839
  24. [35]Allegra CJ Rumble RB Hamilton SR Mangu PB Roach N Hantel A Schilsky RL Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015 J Clin Oncol 2016 34 179 185 26438111
  25. [36]De Roock W Jonker DJ Di Nicolantonio F Sartore-Bianchi A Tu D Siena S Lamba S Arena S Frattini M Piessevaux H Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 2010 304 1812 1820 20978259
  26. [37]Tejpar S Celik I Schlichting M Sartorius U Bokemeyer C Van Cutsem E Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 2012 30 3570 3577 22734028
  27. [38]De Roock W Claes B Bernasconi D De Schutter J Biesmans B Fountzilas G Kalogeras KT Kotoula V Papamichael D Laurent-Puig P Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 2010 11 753 762 20619739
  28. [39]Bozzetti C Negri FV Azzoni C Naldi N Nizzoli R Bortesi B Zobbi V Bottarelli L Tiseo M Silini EM Ardizzoni A Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples Diagn Cytopathol 2013 41 595 598 22833420
  29. [40]Mohamed Suhaimi NA Foong YM Lee DY Phyo WM Cima I Lee EX Goh WL Lim WY Chia KS Kong SL Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients Mol Oncol 2015 9 850 860 25605225 PMC5528778
  30. [41]Isler JA Vesterqvist OE Burczynski ME Analytical validation of genotyping assays in the biomarker laboratory Pharmacogenomics 2007 8 353 368 17391073
  31. [42]Linardou H Briasoulis E Dahabreh IJ Mountzios G Papadimitriou C Papadopoulos S Bafaloukos D Kosmidis P Murray S All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer Cancer Treat Rev 2011 37 221 233 20817364
  32. [43]Cross J DxS Ltd Pharmacogenomics 2008 9 463 467 18384259
  33. [44]Tol J Koopman M Cats A Rodenburg CJ Creemers GJ Schrama JG Erdkamp FL Vos AH van Groeningen CJ Sinnige HA Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 2009 360 563 572 19196673
  34. [45]Fariña Sarasqueta A Moerland E de Bruyne H de Graaf H Vrancken T van Lijnschoten G van den Brule AJ SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics J Mol Diagn 2011 13 199 205 21354055 PMC3128574
  35. [46]Gonzalez de Castro D Angulo B Gomez B Mair D Martinez R Suarez-Gauthier A Shieh F Velez M Brophy VH Lawrence HJ Lopez-Rios F A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens Br J Cancer 2012 107 345 351 22713664 PMC3394984
  36. [47]Harlé A Filhine-Tresarrieu P Husson M Boidot R Rouyer M Dubois C Leroux A Merlin JL Rare RAS mutations in metastatic colorectal Cancer detected during routine RAS genotyping using next generation sequencing Target Oncol 2016 11 363 370 26661077
  37. [48]Dong L Wang S Fu B Wang J Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection Sci Rep 2018 8 9650 30504843 PMC6269532
  38. [49]Taly V Pekin D Benhaim L Kotsopoulos SK Le Corre D Li X Atochin I Link DR Griffiths AD Pallier K Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients Clin Chem 2013 59 1722 1731 23938455
  39. [50]García-Foncillas J Alba E Aranda E Díaz-Rubio E López-López R Tabernero J Vivancos A Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review Ann Oncol 2017 28 2943 2949 28945877 PMC5834030
  40. [52]Thierry AR Mouliere F El Messaoudi S Mollevi C Lopez-Crapez E Rolet F Gillet B Gongora C Dechelotte P Robert B Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat Med 2014 20 430 435 24658074
  41. [53]Van Cutsem E Köhne CH Láng I Folprecht G Nowacki MP Cascinu S Shchepotin I Maurel J Cunningham D Tejpar S Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 2011 29 2011 2019 21502544
  42. [54]Normanno N Cervantes A Ciardiello F De Luca A Pinto C The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios Cancer Treat Rev 2018 70 1 8 30053724
  43. [55]Diehl F Schmidt K Choti MA Romans K Goodman S Li M Thornton K Agrawal N Sokoll L Szabo SA Circulating mutant DNA to assess tumor dynamics Nat Med 2008 14 985 990 18670422 PMC2820391
  44. [56]Garcia J Forestier J Dusserre E Wozny AS Geiguer F Merle P Tissot C Ferraro-Peyret C Jones FS Edelstein DL Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR biorad detection assay, BEAMing assay, and NGS strategy) Oncotarget 2018 9 21122 21131 29765524 PMC5940402
  45. [57]Tabernero J Lenz HJ Siena S Sobrero A Falcone A Ychou M Humblet Y Bouché O Mineur L Barone C Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial Lancet Oncol 2015 16 937 948 26184520 PMC7513622
  46. [58]Papke B Der CJ Drugging RAS: know the enemy Science 2017 355 1158 1163 28302824
  47. [59]Ostrem JM Shokat KM Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design Nat Rev Drug Discov 2016 15 771 785 27469033
  48. [60]Passiglia F Malapelle U Del Re M Righi L Pagni F Furlan D Danesi R Troncone G Novello S KRAS inhibition in non-small cell lung cancer: past failures, new findings and upcoming challenges Eur J Cancer 2020 137 57 68 32745965
  49. [61]Nagasaka M Li Y Sukari A Ou SI Al-Hallak MN Azmi AS KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev 2020 84 101974 32014824 PMC7041424
  50. [62]Serna-Blasco R Sanz-Álvarez M Aguilera Ó García-Foncillas J Targeting the RAS-dependent chemoresistance: the Warburg connection Semin Cancer Biol 2019 54 80 90 29432815
  51. [68]Christensen JG Olson P Briere T Wiel C Bergo MO Targeting Kras(g12c) -mutant cancer with a mutation-specific inhibitor J Intern Med 2020 288 183 191 32176377
  52. [70]Gentile DR Rathinaswamy MK Jenkins ML Moss SM Siempelkamp BD Renslo AR Burke JE Shokat KM Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States Cell Chem Biol 2017 24 1455 1466 29033317 PMC5915340
  53. [72]Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation. 2021. https://ir.mirati.com/press-releases/press-release-details/2021/Mirati-Therapeutics-Adagrasib-Receives-Breakthrough-Therapy-Designation-from-U.S.-Food-and-Drug-Administration-for-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer-Harboring-the-KRAS-G12C-Mutation/default.aspx.
  54. [73]Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data. 2020. https://ir.mirati.com/press-releases/press-release-details/2020/Mirati-Therapeutics-Reports-Investigational-Adagrasib-MRTX849-Preliminary-Data-Demonstrating-Tolerability-and-Durable-Anti-Tumor-Activity-as-well-as-Initial-MRTX1133-Preclinical-Data/default.aspx.
  55. [75]Maurer T Garrenton LS Oh A Pitts K Anderson DJ Skelton NJ Fauber BP Pan B Malek S Stokoe D Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity Proc Natl Acad Sci U S A 2012 109 5299 5304 22431598 PMC3325706
  56. [76]Sun Q Burke JP Phan J Burns MC Olejniczak ET Waterson AG Lee T Rossanese OW Fesik SW Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation Angew Chem Int Ed Eng 2012 51 6140 6143 PMC3620661 22566140
  57. [77]Shima F Yoshikawa Y Ye M Araki M Matsumoto S Liao J Hu L Sugimoto T Ijiri Y Takeda A In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction Proc Natl Acad Sci U S A 2013 110 8182 8187 23630290 PMC3657810
  58. [78]Burns MC Sun Q Daniels RN Camper D Kennedy JP Phan J Olejniczak ET Lee T Waterson AG Rossanese OW Fesik SW Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange Proc Natl Acad Sci U S A 2014 111 3401 3406 24550516 PMC3948241
  59. [80]Hofmann MH Gmachl M Ramharter J Savarese F Gerlach D Marszalek JR Sanderson MP Kessler D Trapani F Arnhof H BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition Cancer Discov 2021 11 142 157 32816843 PMC7892644
  60. [81]Li W Nishimura R Kashishian A Batzer AG Kim WJ Cooper JA Schlessinger J A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase Mol Cell Biol 1994 14 509 517 8264620 PMC358401
  61. [87]Liu C Lu H Wang H Loo A Zhang X Yang G Kowal C Delach S Wang Y Goldoni S Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling Clin Cancer Res 2021 27 342 354 33046519
  62. [88]Quintana E Schulze CJ Myers DR Choy TJ Mordec K Wildes D Shifrin NT Belwafa A Koltun ES Gill AL Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment Cancer Res 2020 80 2889 2902 32350067
  63. [89]End DW Smets G Todd AV Applegate TL Fuery CJ Angibaud P Venet M Sanz G Poignet H Skrzat S Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res 2001 61 131 137 11196150
  64. [90]Whitehead RP McCoy S Macdonald JS Rivkin SE Neubauer MA Dakhil SR Lenz HJ Tanaka MS Abbruzzese JL Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a southwest oncology group study Investig New Drugs 2006 24 335 341 16683076
  65. [91]Rao S Cunningham D de Gramont A Scheithauer W Smakal M Humblet Y Kourteva G Iveson T Andre T Dostalova J Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer J Clin Oncol 2004 22 3950 3957 15459217
  66. [93]Marín-Ramos NI Balabasquer M Ortega-Nogales FJ Torrecillas IR Gil-Ordóñez A Marcos-Ramiro B Aguilar-Garrido P Cushman I Romero A Medrano FJ A potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) inhibitor improves survival in Ras-driven acute myeloid leukemia J Med Chem 2019 62 6035 6046 31181882
  67. [94]Chandra A Grecco HE Pisupati V Perera D Cassidy L Skoulidis F Ismail SA Hedberg C Hanzal-Bayer M Venkitaraman AR The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins Nat Cell Biol 2011 14 148 158 22179043
  68. [95]Zimmermann G Papke B Ismail S Vartak N Chandra A Hoffmann M Hahn SA Triola G Wittinghofer A Bastiaens PI Waldmann H Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling Nature 2013 497 638 642 23698361
  69. [96]Klein CH Truxius DC Vogel HA Harizanova J Murarka S Martín-Gago P Bastiaens PIH PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas Int J Cancer 2019 144 767 776 30194764 PMC6519276
  70. [97]Martín-Gago P Fansa EK Klein CH Murarka S Janning P Schürmann M Metz M Ismail S Schultz-Fademrecht C Baumann M A PDE6δ-KRas inhibitor Chemotype with up to seven H-bonds and Picomolar affinity that prevents efficient inhibitor release by Arl2 Angew Chem Int Ed Eng 2017 56 2423 2428 28106325
  71. [98]Cheng J Li Y Wang X Dong G Sheng C Discovery of novel PDEδ degraders for the treatment of KRAS mutant colorectal Cancer J Med Chem 2020 63 7892 7905 32603594
  72. [99]Fang JY Richardson BC The MAPK signalling pathways and colorectal cancer Lancet Oncol 2005 6 322 327 15863380
  73. [100]Roskoski R Jr ERK1/2 MAP kinases: structure, function, and regulation Pharmacol Res 2012 66 105 143 22569528
  74. [101]Peng SB Henry JR Kaufman MD Lu WP Smith BD Vogeti S Rutkoski TJ Wise S Chun L Zhang Y Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers Cancer Cell 2015 28 384 398 26343583
  75. [102]Vakana E Pratt S Blosser W Dowless M Simpson N Yuan XJ Jaken S Manro J Stephens J Zhang Y LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer Oncotarget 2017 8 9251 9266 27999210 PMC5354729
  76. [103]Yao YM Donoho GP Iversen PW Zhang Y Van Horn RD Forest A Novosiadly RD Webster YW Ebert P Bray S Mouse PDX trial suggests synergy of concurrent inhibition of RAF and EGFR in colorectal Cancer with BRAF or KRAS mutations Clin Cancer Res 2017 23 5547 5560 28611205
  77. [104]Sullivan RJ Hollebecque A Flaherty KT Shapiro GI Rodon Ahnert J Millward MJ Zhang W Gao L Sykes A Willard MD A phase I study of LY3009120, a Pan-RAF inhibitor, in patients with advanced or metastatic Cancer Mol Cancer Ther 2020 19 460 467 31645440
  78. [105]Desai J Gan H Barrow C Jameson M Atkinson V Haydon A Millward M Begbie S Brown M Markman B Phase I, open-label, dose-escalation/dose-expansion study of Lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors J Clin Oncol 2020 38 2140 2150 32182156 PMC7325368
  79. [106]Zimmer L Barlesi F Martinez-Garcia M Dieras V Schellens JH Spano JP Middleton MR Calvo E Paz-Ares L Larkin J Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations Clin Cancer Res 2014 20 4251 4261 24947927
  80. [109]Pratilas CA Taylor BS Ye Q Viale A Sander C Solit DB Rosen N: (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway Proc Natl Acad Sci U S A 2009 106 4519 4524 19251651 PMC2649208
  81. [110]Lamba S Russo M Sun C Lazzari L Cancelliere C Grernrum W Lieftink C Bernards R Di Nicolantonio F Bardelli A RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells Cell Rep 2014 8 1475 1483 25199829
  82. [111]Yen I Shanahan F Merchant M Orr C Hunsaker T Durk M La H Zhang X Martin SE Lin E Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors Cancer Cell 2018 34 611 625 30300582
  83. [112]Xu H Zhou S Xia H Yu H Tang Q Bi F MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells Cell Death Differ 2019 26 2400 2415 30833665 PMC6889282
  84. [113]Dai X Xia H Zhou S Tang Q Bi F Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers Cancer Lett 2019 442 202 212 30429107
  85. [114]Varga A Soria JC Hollebecque A LoRusso P Bendell J Huang SA Wagle MC Okrah K Liu L Murray E A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors Clin Cancer Res 2020 26 1229 1236 31848189
  86. [115]Merchant M Moffat J Schaefer G Chan J Wang X Orr C Cheng J Hunsaker T Shao L Wang SJ Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors PLoS One 2017 12 e0185862 28982154 PMC5628883
  87. [116]Mallucci L Wells V The end of KRAS, and other, cancers? A new way forward Drug Discov Today 2014 19 383 387 24291216
  88. [118]Köhler J Zhao Y Li J Gokhale PC Tiv HL Knott AR Wilkens MK Soroko KM Lin M Ambrogio C ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung Cancer Mol Cancer Ther 2021 20 641 654 33536188 PMC8026682
  89. [119]Martinelli E Troiani T D'Aiuto E Morgillo F Vitagliano D Capasso A Costantino S Ciuffreda LP Merolla F Vecchione L Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells Int J Cancer 2013 133 2089 2101 23629727
  90. [120]Do K Speranza G Bishop R Khin S Rubinstein L Kinders RJ Datiles M Eugeni M Lam MH Doyle LA Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer Investig New Drugs 2015 33 720 728 25637165 PMC7709950
  91. [122]Ramanathan RK Von Hoff DD Eskens F Blumenschein G Jr Richards D Genvresse I Reschke S Granvil C Skubala A Peña C Mross K Phase Ib trial of the PI3K inhibitor Copanlisib combined with the allosteric MEK inhibitor Refametinib in patients with advanced Cancer Target Oncol 2020 15 163 174 32314268 PMC7591420
  92. [123]Tsubaki M Takeda T Noguchi M Jinushi M Seki S Morii Y Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells Cancers (Basel) 2019 11 1866 1884 PMC6966459 31769426
  93. [124]Wee S Jagani Z Xiang KX Loo A Dorsch M Yao YM Sellers WR Lengauer C Stegmeier F PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 2009 69 4286 4293 19401449
  94. [126]Alexandrov LB Nik-Zainal S Wedge DC Aparicio SA Behjati S Biankin AV Bignell GR Bolli N Borg A Børresen-Dale AL Signatures of mutational processes in human cancer Nature 2013 500 415 421 23945592 PMC3776390
  95. [127]Patnaik A Kang SP Rasco D Papadopoulos KP Elassaiss-Schaap J Beeram M Drengler R Chen C Smith L Espino G Phase I study of Pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors Clin Cancer Res 2015 21 4286 4293 25977344
  96. [128]Liu J Huang X Liu H Wei C Ru H Qin H Lai H Meng Y Wu G Xie W Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients J Transl Med 2021 19 27 33413474 PMC7789428
  97. [129]Lal N White BS Goussous G Pickles O Mason MJ Beggs AD Taniere P Willcox BE Guinney J Middleton GW KRAS mutation and consensus molecular subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal Cancer Clin Cancer Res 2018 24 224 233 29061646 PMC5777581
  98. [130]Poon E Mullins S Watkins A Williams GS Koopmann JO Di Genova G Cumberbatch M Veldman-Jones M Grosskurth SE Sah V The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment J Immunother Cancer 2017 5 63 28807001 PMC5557252
  99. [135]Cohn A Morse MA O'Neil B Whiting S Coeshott C Ferraro J Bellgrau D Apelian D Rodell TC Whole recombinant Saccharomyces cerevisiae yeast expressing Ras mutations as treatment for patients with solid tumors bearing Ras mutations: results from a phase 1 trial J Immunother 2018 41 141 150 29528991 PMC5895167
  100. [137]Guinney J Dienstmann R Wang X de Reyniès A Schlicker A Soneson C Marisa L Roepman P Nyamundanda G Angelino P The consensus molecular subtypes of colorectal cancer Nat Med 2015 21 1350 1356 26457759 PMC4636487

Cited by

Sorted by citations

Authors
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F.
Affiliations
Sichuan University (CN)
Corresponding author
Bi, Feng
ORCID
Venue
Molecular Cancer
Publisher
Springer Science and Business Media LLC
Published
2021-11-06
Volume
20
Issue
1
Pages
143-143
ISSN
1476-4598 (ISSN-L)
DOI
10.1186/s12943-021-01441-4
PMC
PMC8571891
OpenAlex
W3213334042
Cited by
482
References
36
Citations by year
2026: 82 · 2025: 155 · 2024: 140 · 2023: 78 · 2022: 25 · 2021: 1
FWCI
7.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • science and technology department of sichuan province (2019YJ0056)
  • national natural science foundation of china (82073059, 81872020, 81621003, 82073314)
  • 1.3.5 project for disciplines of excellence, west china hospital, sichuan university (ZYGD18005)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
KRAS mutation, colorectal cancer, oncogenic KRAS, KRAS G12C inhibitors, KRAS mutation testing, prognosis, diagnosis, targeted therapy, downstream signaling pathways, metastatic colorectal cancer
MeSH terms
Liquid Biopsy, Drug Development, Combined Modality Therapy, Disease Susceptibility, Humans, Mutation, Oncogenes, Prognosis, Sensitivity and Specificity, Structure-Activity Relationship, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease Management, Molecular Diagnostic Techniques, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review